Literature DB >> 24229708

Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.

You-Soub Lee1, Jung-Won Lee, Ju-Won Jang, Xin-Zi Chi, Jang-Hyun Kim, Ying-Hui Li, Min-Kyu Kim, Da-Mi Kim, Byeung-Sub Choi, Eung-Gook Kim, Jin-Haeng Chung, Ok-Jun Lee, You-Mie Lee, Joo-Won Suh, Linda Shyue Huey Chuang, Yoshiaki Ito, Suk-Chul Bae.   

Abstract

Targeted inactivation of Runx3 in mouse lung induced mucinous and nonmucinous adenomas and markedly shortened latency of adenocarcinoma formation induced by oncogenic K-Ras. RUNX3 was frequently inactivated in K-RAS mutated human lung adenocarcinomas. A functional genetic screen of a fly mutant library and molecular analysis in cultured cell lines revealed that Runx3 forms a complex with BRD2 in a K-Ras-dependent manner in the early phase of the cell cycle; this complex induces expression of p14(ARF)/p19(Arf) and p21(WAF/CIP). When K-Ras was constitutively activated, the Runx3-BRD2 complex was stably maintained and expression of both p14(ARF) and p21(WAF/CIP) was prolonged. These results provide a missing link between oncogenic K-Ras and the p14(ARF)-p53 pathway, and may explain how cells defend against oncogenic K-Ras.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229708     DOI: 10.1016/j.ccr.2013.10.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  59 in total

1.  RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.

Authors:  Martin C Whittle; Kamel Izeradjene; P Geetha Rani; Libing Feng; Markus A Carlson; Kathleen E DelGiorno; Laura D Wood; Michael Goggins; Ralph H Hruban; Amy E Chang; Philamer Calses; Shelley M Thorsen; Sunil R Hingorani
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

Review 2.  Lineage factors and differentiation states in lung cancer progression.

Authors:  W K C Cheung; D X Nguyen
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

3.  Aurora kinase and RUNX: Reaching beyond transcription.

Authors:  Linda Shyue Huey Chuang; Vaidehi Krishnan; Yoshiaki Ito
Journal:  Cell Cycle       Date:  2016-08-05       Impact factor: 4.534

4.  Aurora kinase-induced phosphorylation excludes transcription factor RUNX from the chromatin to facilitate proper mitotic progression.

Authors:  Linda Shyue Huey Chuang; Jian Ming Khor; Soak Kuan Lai; Shubham Garg; Vaidehi Krishnan; Cheng-Gee Koh; Sang Hyun Lee; Yoshiaki Ito
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-23       Impact factor: 11.205

5.  The roles of RUNX3 in cervical cancer cells in vitro.

Authors:  Zhen Li; Pan Fan; Min Deng; Chao Zeng
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

Review 6.  RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Authors:  Bingliang Fang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-07       Impact factor: 3.848

7.  Loss of RUNX1 is associated with aggressive lung adenocarcinomas.

Authors:  Jon Ramsey; Kelly Butnor; Zhihua Peng; Tim Leclair; Jos van der Velden; Gary Stein; Jane Lian; C Matthew Kinsey
Journal:  J Cell Physiol       Date:  2017-11-01       Impact factor: 6.384

8.  Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients.

Authors:  Ka Chen; Hongliang Liu; Zhensheng Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Qingyi Wei
Journal:  Int J Cancer       Date:  2019-02-01       Impact factor: 7.396

Review 9.  Roles of RUNX in Hippo Pathway Signaling.

Authors:  Antonino Passaniti; Jessica L Brusgard; Yiting Qiao; Marius Sudol; Megan Finch-Edmondson
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 10.  Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.

Authors:  Yuewu Yang; Zhiqiang Ye; Zengcheng Zou; Gemin Xiao; Gangjian Luo; Hongzhi Yang
Journal:  Tumour Biol       Date:  2014-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.